Daniel Braun

Daniel Braun asked for color on the underlying reasons for the moderately pushed-out safety data timeline for ALX2004. He followed up by asking if it's safe to expect up to four dose levels to have been tested by the time of the disclosure.

Answer

CEO Jason Lettmann explained that the timeline adjustment for ALX2004 safety data is to ensure the communication of robust, meaningful, and fulsome data from the dose escalation phase, providing greater clarity on the expected therapeutic dose. He confirmed that testing up to four dose levels is a reasonable expectation, noting the rapid clearance of 1 mg/kg and 2 mg/kg without DLTs.

Daniel Braun asked for clarification on the moderate push-out of the ALX2004 safety data timeline, seeking the underlying reasons for this adjustment. He also followed up to confirm if up to four dose levels are expected to have been tested by the time of the disclosure.

Answer

Jason Lettmann, CEO, explained that the timeline adjustment for ALX2004 safety data aims to ensure the communication of robust and meaningful data from the dose escalation phase, providing clearer insights into the expected therapeutic dose range. He confirmed that testing up to four dose levels is a reasonable expectation by the time of the disclosure.